Journal of Breast Cancer最新文献

{"title":"Factors Affecting Health-Related Quality of Life in Patients With Metastatic Breast Cancer.","authors":"Mihai Park, Su-Yeon Yu, Ha-Lim Jeon, Inmyung Song","doi":"10.4048/jbc.2023.26.e29","DOIUrl":"10.4048/jbc.2023.26.e29","url":null,"abstract":"<p><strong>Purpose: </strong>Improving survival and health-related quality of life (HRQOL), along with symptom relief, is important for the treatment of metastatic breast cancer (MBC). This study measured HRQOL and analyzed its influence on sociodemographic and clinical factors in patients with MBC.</p><p><strong>Methods: </strong>We interviewed 298 patients with MBC to investigate their sociodemographic characteristics and HRQOL by using EuroQol-5D-5L (EQ-5D) between September and October 2014. We also reviewed medical records to examine the clinical condition of the patients, including disease progression, adverse events, treatments, chronic disease, and metastatic areas. The distribution of the EQ-5D index was compared between different clinical conditions by using the Kruskal-Wallis test. We also conducted multiple regression analyses to identify the factors affecting HRQOL in patients with MBC.</p><p><strong>Results: </strong>The mean EQ-5D index was 0.79 for all patients surveyed. The mean EQ-5D index score was significantly lower in patients in the progressed state than in those in the progression-free survival state (0.73 vs. 0.80, <i>p</i> = 0.0002). The HRQOL of patients treated with chemotherapy alone was significantly lower than that of patients treated with hormonal or targeted therapy (0.76 vs. 0.82 or 0.85; <i>p</i> = 0.0020). Regression analysis revealed that the clinical factors associated with lower HRQOL were progressed state, chemotherapy, and adverse events, such as hair loss or stomatitis. Finally, young age, high income, and employment were the sociodemographic factors that were positively associated with better HRQOL.</p><p><strong>Conclusion: </strong>This study provides new information on the health utility of MBC patients on the basis of various patient characteristics and offers insights that can assist medical professionals in treating patients with MBC and help policymakers implement cancer strategies. Further research is needed to reflect the changing environment of cancer treatment and enrich available evidence.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":" ","pages":"436-445"},"PeriodicalIF":2.4,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9975199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Expression of NRF2 and Low Expression of KEAP1 Predict Worse Survival in Patients With Operable Triple-Negative Breast Cancer.","authors":"Young Sub Lee, Jun Kang, Eun Sun Jung, Ahwon Lee","doi":"10.4048/jbc.2023.26.e42","DOIUrl":"10.4048/jbc.2023.26.e42","url":null,"abstract":"<p><strong>Purpose: </strong>Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer. Currently, no effective treatment options for this condition exist. Nuclear factor erythroid 2-related factor 2 (NRF2), encoded by nuclear factor erythroid-derived 2-like 2 (<i>NFE2L2</i>) gene and its endogenous inhibitor, Kelch-like ECH-associated protein 1 (KEAP1), both participate in cellular defense mechanisms against oxidative stress and contribute to chemoresistance and tumor progression in numerous types of cancers. This study aimed to evaluate the expression patterns of NRF2 and KEAP1 and their prognostic value in operable TNBC.</p><p><strong>Methods: </strong>Tissue microarrays were prepared using tumor tissues collected from 203 patients with TNBC who underwent surgery. Immunohistochemical staining analyses of NRF2 and KEAP1 were performed. The expression of each immunomarker was categorized into two groups (low or high) based on the median H-score. We analyzed the association between the expression of each immunomarker and clinicopathological information to predict survival. A total of 225 TNBC samples from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset were used to validate our results.</p><p><strong>Results: </strong>NRF2 immunoreactivity was detected in the nucleus and was associated with histologic grade and Ki-67 index, whereas KEAP1 immunoreactivity was detected in the cytoplasm and was associated with the Ki-67 index. Survival analyses showed that NRF2 and KEAP1 expressions were independent prognostic factors for overall survival (OS) (hazard ratio [HR], 2.45 and 0.30; <i>p</i> = 0.015 and 0.016, respectively) and disease-free survival (HR, 2.27 and 0.42; <i>p</i> = 0.019 and 0.022, respectively). <i>NFE2L2</i> mRNA expression was an independent prognostic factor for OS (HR, 0.59; <i>p</i> = 0.009) in the METABRIC dataset.</p><p><strong>Conclusion: </strong>High NRF2 and low KEAP1 expressions independently predicted poor survival in patients with operable TNBC. Further investigations are warranted to examine the possible therapeutic benefits of targeting the KEAP1-NRF2 pathway for TNBC treatment.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 5","pages":"461-478"},"PeriodicalIF":2.4,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71481923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudoangiomatous Stromal Hyperplasia of the Breast in a Female Adolescent Presenting as Bilateral Gigantomastia.","authors":"Soo Hyun Woo,&nbsp;Hyunil Kang,&nbsp;Woo Jung Choi,&nbsp;Eun Key Kim","doi":"10.4048/jbc.2023.26.e21","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e21","url":null,"abstract":"<p><p>Pseudoangiomatous stromal hyperplasia (PASH) is a rare idiopathic proliferative mesenchymal breast disease related to hormonal imbalance, and thus extremely rare in children and adolescents. In addition, PASH manifests as a bilateral gigantomastia in some cases with no established cause or treatment. Here, we report a case of a rapidly developed PASH presenting with bilateral gigantomastia in a 14-year-old premenarchial female patient. Considering the patient's age and emotions and the need for nipple-areolar complex repositioning, we performed reduction mammoplasty rather than total mastectomy despite the possibility of recurrence. Although some masses could not be completely removed, no complications, such as infection, wound dehiscence, or hematoma occurred postoperatively. The patient was stable during the 18-month follow-up period, although an evidence of recurrent and residual disease was noted upon ultrasonography.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 4","pages":"391-396"},"PeriodicalIF":2.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/2a/jbc-26-391.PMC10475705.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10511498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Radiation Induced Low-Grade Myofibroblastic Sarcoma in the Retropectoral Area After Breast Conserving Surgery: A Case Report.","authors":"Seo Young Park,&nbsp;Hye Jung Kim,&nbsp;Jeeyeon Lee,&nbsp;Ji Yun Jeong,&nbsp;Jungsup Byun,&nbsp;Won Hwa Kim,&nbsp;Byunggeon Park,&nbsp;Jihoon Hong","doi":"10.4048/jbc.2023.26.e36","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e36","url":null,"abstract":"<p><p>Low-grade myofibroblastic sarcoma (LGMFS) is a rare type of sarcoma, and its manifestation as a radiotherapy (RT)-induced sarcoma following RT for breast cancer is even more unusual. To date, only one case of RT-induced mammary myofibroblastic sarcoma (MFS) has been reported. Here we present the case of a 49-year-old woman with LGMFS after undergoing breast-conserving surgery for invasive ductal carcinoma (IDC), and with a history of RT 16 years prior. Due to the rarity of this disease, previous studies have focused primarily on the pathological findings of MFS. In this report however, we present the clinical and radiological features of LGMFS in the retro pectoral area as a rare type of RT-induced sarcoma.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 4","pages":"397-402"},"PeriodicalIF":2.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/b1/jbc-26-397.PMC10475708.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10161457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Waiting Time for Breast Cancer Treatment in Korea: A Nationwide Cohort Study.","authors":"Young-Jin Lee,&nbsp;Jae Ho Jeong,&nbsp;Jinhong Jung,&nbsp;Tae-Kyung Yoo,&nbsp;Sae Byul Lee,&nbsp;Jisun Kim,&nbsp;Beom Seok Ko,&nbsp;Hee Jeong Kim,&nbsp;Jong Won Lee,&nbsp;Byung Ho Son,&nbsp;Il Yong Chung","doi":"10.4048/jbc.2023.26.e26","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e26","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to analyze the waiting time for initial treatment after breast cancer diagnosis and determine the factors influencing treatment delay in South Korea.</p><p><strong>Methods: </strong>This nationwide retrospective cohort study was conducted using the Health Insurance Review and Assessment data. The participants were classified according to the regions where their biopsy and treatment were performed (Seoul-Seoul, Metro-Metro, Other-Other, Metro-Seoul, Other-Seoul). Waiting time was analyzed according to regional subgroup, year of diagnosis, and type of treatment. Multivariable logistic regression models were constructed to identify the factors associated with treatment delay (after 30 days of diagnosis).</p><p><strong>Results: </strong>A total of 133,514 participants newly diagnosed between January 2010 and December 2017 were included in the study. The median waiting time for initial treatment in the total population increased from 8 days, in 2010, to 14 days, in 2017. In the Seoul-Seoul group, the waiting time increased from 10 days, in 2010, to 16 days, in 2017. Although the median waiting time was approximately 10 days in the Metro-Metro and Other-Other groups, it was 27 and 24 days, in the Metro-Seoul and Other-Seoul group, respectively, in 2017. The proportion of delayed upfront surgery by more than 30 days was higher in the Metro-Seoul (odds ratio [OR], 8.088; 95% confidence interval [CI], 7.357-8.893; <i>p</i> < 0.001) and Other-Seoul (OR, 6.210; 95% CI, 5.717-6.750; <i>p</i> < 0.001) groups than in the Metro-Metro (OR, 1.468; 95% CI, 1.352-1.594; <i>p</i> < 0.001) and Other-Other (reference) groups. Previous medical history and treatment at tertiary hospital were observed as factors related to delayed surgery.</p><p><strong>Conclusion: </strong>Waiting times for breast cancer surgery have increased across all regions of Korea, with those traveling to Seoul experiencing particularly long wait times.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 4","pages":"334-343"},"PeriodicalIF":2.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/46/jbc-26-334.PMC10475710.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Quality of Life and Cosmetic Outcome of Latissimus Dorsi Mini-Flap With Breast Conservation Surgery Without Reconstruction.","authors":"Jang-Il Kim,&nbsp;Jong-Ho Cheun,&nbsp;Ji Gwang Jung,&nbsp;Yumi Kim,&nbsp;Changjin Lim,&nbsp;Yireh Han,&nbsp;Sookyoung Jeon,&nbsp;Ki Yong Hong,&nbsp;Han-Byoel Lee,&nbsp;Wonshik Han","doi":"10.4048/jbc.2023.26.e33","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e33","url":null,"abstract":"<p><strong>Purpose: </strong>Latissimus dorsi mini-flap (LDMF) reconstruction after breast-conserving surgery (BCS) is a useful volume replacement technique when a large tumor is located in the upper or outer portion of the breast. However, few studies have reported the impact of LDMF on patients' quality of life (QoL) and cosmesis compared with conventional BCS.</p><p><strong>Methods: </strong>We identified patients who underwent BCS with or without LDMF between 2010 and 2020 at a single center. At least 1 year after surgery, we prospectively administered the BREAST-Q to assess QoL and obtained the patients' breast photographs. The cosmetic outcome was assessed using four panels composed of physicians and the BCCT.core software.</p><p><strong>Results: </strong>A total of 120 patients were enrolled, of whom 62 and 58 underwent LDMF or BCS only, respectively. The LDMF group had significantly larger tumors, shorter nipple-to-tumor distances in preoperative examinations, and larger resected breast volumes than did the BCS-only group (<i>p</i> < 0.001). The questionnaires revealed that QoL was poorer in the LDMF group, particularly in terms of the physical well-being score (40.9 vs. 20.1, <i>p</i> < 0.001). Notably, the level of patients' cosmetic satisfaction with their breasts was comparable, and the cosmetic evaluation was assessed by panels and the BCCT.core software showed no differences between the groups.</p><p><strong>Conclusion: </strong>Our results showed that cosmetic outcomes of performing LDMF are comparable to those of BCS alone while having the advantage of resecting larger volumes of breast tissue. Therefore, for those who strongly wish to preserve the cosmesis of their breasts, LDMF can be considered a favorable surgical option after the patient is oriented toward the potential for physical dysfunction after surgery.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 4","pages":"344-352"},"PeriodicalIF":2.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/2b/jbc-26-344.PMC10475706.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Diffusion-Weighted Magnetic Resonance Imaging for Preoperative Evaluation of Patients With Breast Cancer: Protocol of a Prospective, Multicenter, Observational Cohort Study.","authors":"Vivian Youngjean Park,&nbsp;Hee Jung Shin,&nbsp;Bong Joo Kang,&nbsp;Min Jung Kim,&nbsp;Woo Kyung Moon,&nbsp;Sung Eun Song,&nbsp;Su Min Ha","doi":"10.4048/jbc.2023.26.e32","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e32","url":null,"abstract":"<p><p>This corrects the article on p. 292 in vol. 26, PMID: 37272245.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 4","pages":"403"},"PeriodicalIF":2.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/6c/jbc-26-403.PMC10475709.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant <i>PIK3CA</i> and <i>TP53</i> Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis.","authors":"Xiao-Yi Lin,&nbsp;Lijuan Guo,&nbsp;Xin Lin,&nbsp;Yulei Wang,&nbsp;Guochun Zhang","doi":"10.4048/jbc.2023.26.e30","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e30","url":null,"abstract":"<p><strong>Purpose: </strong><i>PIK3CA</i> and <i>TP53</i> are the most prevalently mutated genes in breast cancer (BC). Previous studies have indicated an association between concomitant <i>PIK3CA/TP53</i> mutations and shorter disease-free survival. As its clinical utility remains largely unknown, we aimed to analyze the prognostic and predictive roles of this co-mutation.</p><p><strong>Methods: </strong>We retrospectively analyzed patients who were diagnosed with BC at Guangdong Provincial People's Hospital (GDPH) who underwent next-generation sequencing. The correlation of concomitant <i>PIK3CA/TP53</i> mutations with clinicopathological and mutational characteristics, and neoadjuvant systemic therapy (NST) responses was analyzed. The Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset was used to verify associations between concurrent mutations and survival outcomes.</p><p><strong>Results: </strong>In the GDPH cohort, concomitant <i>PIK3CA/TP53</i> mutations were associated with more aggressive phenotypes, including human epidermal growth factor receptor 2 positive status, hormone receptor negative status, high Ki-67 expression, high histological grade, advanced TNM stage, and additional genetic alterations. Co-mutations also portended a worse response to NST, especially taxane-containing regimens, when compared with the <i>TP53</i> mutant alone (odds ratio, 3.767; 95% confidence interval, 1.205-13.087; <i>p</i> = 0.028). A significant association was observed between concomitant <i>PIK3CA/TP53</i> mutations and poor survival outcomes in the METABRIC cohort.</p><p><strong>Conclusion: </strong>Concomitant <i>PIK3CA/TP53</i> mutations not only suggested unfavorable features and poor prognosis in BC but also conferred less benefit to NST than <i>TP53</i> mutations alone.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 4","pages":"363-377"},"PeriodicalIF":2.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/21/jbc-26-363.PMC10475711.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review.","authors":"Seongwoo Yang,&nbsp;Seong Won Park,&nbsp;Soong June Bae,&nbsp;Sung Gwe Ahn,&nbsp;Joon Jeong,&nbsp;Kyounghoon Park","doi":"10.4048/jbc.2023.26.e22","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e22","url":null,"abstract":"<p><strong>Purpose: </strong>Adherence and persistence to adjuvant hormone therapy (AHT) are seldom maintained among early-stage hormone receptor-positive breast cancer (BC) survivors, despite the significant clinical benefits of long-term AHT. As the factors influencing adherence to AHT remain unclear, this study aimed to comprehensively identify such factors and classify them into specific dimensions.</p><p><strong>Methods: </strong>PubMed, Cochrane Library, Embase, PsycINFO, and CINAHL were searched for qualified articles. The search mainly focused on three components: early-stage (0-III) BC, oral AHT administration, and adherence to AHT, with keywords derived from MeSH and entry terms. The factors identified were then classified into six categories based on a modified WHO multidimensional model.</p><p><strong>Results: </strong>Overall, 146 studies were included; the median sample size was 651 (range, 31-40,009), and the mean age of the population was 61.5 years (standard deviation, 8.3 years). Patient- and therapy-related factors were the most frequently investigated factors. Necessity/concern beliefs and self-efficacy among patient-related factors were consistently related to better adherence than depression. Although drug side effects and medication use cannot be modified easily, a refined prescription strategy for the initiation and switching of AHT is likely to increase adherence levels.</p><p><strong>Conclusion: </strong>An effective psychological program that encourages positive views and beliefs about medication and management strategies for each therapy may be necessary to improve adherence to AHT. Social support and a sense of belonging can be enhanced through community participation and social media for better adherence to AHT. Patient-centered communication and appropriate recommendations by physicians may be attributable to better adherence outcomes. Findings from systematically organized factors that influence adherence to AHT may contribute to the establishment of intervention strategies to benefit patients with early-stage BC to achieve optimal health.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 4","pages":"309-333"},"PeriodicalIF":2.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/3d/jbc-26-309.PMC10475712.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10213974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>AURKA</i> Gene Variants rs1047972, and rs8173 Are Associated With Breast Cancer.","authors":"Eric Jonathan Maciel-Cruz,&nbsp;Luis Eduardo Figuera-Villanueva,&nbsp;Asbiel Felipe Garibaldi-Ríos,&nbsp;Belinda Claudia Gómez-Meda,&nbsp;Guillermo Moisés Zúñiga-González,&nbsp;Ana María Pérez,&nbsp;Paola B Castro-García,&nbsp;Ramiro Ramírez-Patiño,&nbsp;Martha Patricia Gallegos-Arreola","doi":"10.4048/jbc.2023.26.e31","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e31","url":null,"abstract":"<p><strong>Purpose: </strong>Association between variants rs1047972 and rs8173 of the <i>AURKA</i> gene in healthy women and breast cancer (BC) in a Mexican population.</p><p><strong>Methods: </strong>Genomic DNA samples from 409 healthy women and 572 patients with BC were analyzed for variants rs1047972 and rs8173 of the <i>AURKA</i> gene by polymerase chain reaction-restriction fragment length polymorphism.</p><p><strong>Results: </strong>TT genotype (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.22-5.11; <i>p</i> = 0.0015) and the T allele (OR, 1.16; 95% CI, 1.23-2.12; <i>p</i> = 0.0007) of the rs1047972 variant were associated as risk susceptibility for BC relative to the control group. Contrarily, the GG genotype (OR, 0.64; 95% CI, 0.43-0.94; <i>p</i> = 0.029) was associated as a protective factor of susceptibility of BC of the variant rs8173 of the <i>AURKA</i> gene. Differences were observed in the patients with BC who were carriers of the CT genotype of the rs1047972 variant with overweight, obesity, estrogen receptor-positive plus obesity, Ki-67 (≥ 20%) plus history familial positive of cancer; and for variant rs8173 the BC patients who were CG carriers and presented chemotherapy gastric toxicity, hormonal receptor positive plus chemotherapy gastric toxicity, and menopause status plus chemotherapy gastric toxicity (<i>p</i> < 0.05). Two common haplotypes were identified in the study groups: CG and TC genotypes, were associated as a protective and risk factor, respectively (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Variants rs1047972 and rs8173 of the <i>AURKA</i> gene and the TC haplotype were associated as risk susceptibility factors for BC in this population.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"26 4","pages":"378-390"},"PeriodicalIF":2.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/3b/jbc-26-378.PMC10475707.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}